Company: IPSC
Filing Date: 2025-07-07
Form Type: 8-K
Source: 0001104659-25-066091
Chunk: 0

Company: Century Therapeutics, Inc.
Filing Date: 2025-07-07
Form: 8-K
Item: Item 2.05
Chunk 0
---
Item 2.05      Costs Associated with Exit or Disposal Activities  

On July 1, 2025, the Board of Directors (the “ Board”)
of Century Therapeutics, Inc. (the “ Company”) approved a reduction in force as part of a broader effort to right size
the organization to focus on programs with the highest potential for transformational value. The Company expects to implement a net reduction
of its employee headcount by approximately 51% (the “ RIF”). As part of the RIF, the Company estimates that it will
incur charges of approximately $3.7 million for severance and other employee termination-related costs. These costs consist primarily
of cash expenditures related to severance payments. The Company estimates that the workforce reduction will be substantially completed
by the end of the third quarter of 2025.

The estimate of costs that the Company expects to incur, and the timing
thereof are subject to a number of assumptions and actual results may differ. The Company may also incur additional costs not currently
contemplated due to events that may occur as a result of, or that are associated with, the actions described above.